Abstract:Inactivating mutations in PTEN are prevalent in melanoma and are thought to support tumor development by hyperactivating the AKT/mTOR pathway. Conversely, activating mutations in AKT are relatively rare in melanoma, and therapies targeting AKT or mTOR have shown disappointing outcomes in preclinical models and clinical trials of melanoma. This has led to the speculation that PTEN suppresses melanoma by opposing AKT-independent pathways, potentially through noncanonical functions beyond its lipid phosphatase activity. In this study, we examined the mechanisms of PTEN-mediated suppression of melanoma formation through the restoration of various PTEN functions in PTEN-deficient cells or mouse models. PTEN lipid phosphatase activity predominantly inhibited melanoma cell proliferation, invasion, and tumor growth, with minimal contribution from its protein phosphatase and scaffold functions. A drug screen underscored the exquisite dependence of PTEN-deficient melanoma cells on the AKT/mTOR pathway. Furthermore, activation of AKT alone was sufficient to counteract several aspects of PTEN-mediated melanoma suppression, particularly invasion and the growth of allograft tumors. Phosphoproteomics analysis of the lipid phosphatase activity of PTEN validated its potent inhibition of AKT and many of its known targets, while also identifying the AP-1 transcription factor FRA1 as a downstream effector. The restoration of PTEN dampened FRA1 translation by inhibiting AKT/mTOR signaling, and FRA1 overexpression negated aspects of PTEN-mediated melanoma suppression akin to AKT. This study supports AKT as the key mediator of PTEN inactivation in melanoma and identifies an AKT/mTOR/FRA1 axis as a driver of melanomagenesis. Significance: PTEN suppresses melanoma predominantly through its lipid phosphatase function, which when lost, elevates FRA1 levels through AKT/mTOR signaling to promote several aspects of melanomagenesis.

FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

Mtorc1 Accelerates Osteosarcoma Progression Via M6a-Dependent Stabilization of USP7 Mrna

Expression Profiling Reveals Transcriptional Regulation by Fbxw7/Mtor Pathway in Radiation-Induced Mouse Thymic Lymphomas

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells.

Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development.

Enhanced Sensitivity of Pten-Deficient Tumors to Inhibition of Frap/Mtor

Inhibition of the AKT/mTOR pathway negatively regulates PTEN expression via miRNAs

FBXW7 in breast cancer: mechanism of action and therapeutic potential

The FBXW7-SHOC2-Raptor Axis Controls the Cross-Talks between the RAS-ERK and mTORC1 Signaling Pathways.

FBXW7 attenuates tumor drug resistance and enhances the efficacy of immunotherapy

Epidermal growth factor receptor (EGFR) is a target of the tumor-suppressor E3 ligase FBXW7

Mtor Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer

USP10 Suppresses Tumor Progression by Inhibiting Mtor Activation in Hepatocellular Carcinoma.

Molecular insights and clinical implications for the tumor suppressor role of SCFFBXW7 E3 ubiquitin ligase

PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis

Clinical significance of FBXW7 loss of function in human cancers

The FBXW7-SHOC2-Raptor axis controls the cross-talks between RAS/ERK and mTORC1 signaling pathways

Function and regulation of F-box/WD repeat-containing protein 7

New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists

Recurrent mutations in tumor suppressor FBXW7 bypass Wnt/β-catenin addiction in cancer